Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07810985) titled 'Bismuth Quadruple Therapy Versus Modified Bismuth Therapy for Helicobacter Pylori' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Reham Abdelkader Elkhouly
Condition:
Helicobacter Eradication
Intervention:
Drug: Bismuth added on triple therapy
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 1, 2023
Target Sample Size: 200
Countries of Recruitment:
Egypt
To know more, visit https://clinicaltrials.gov/study/NCT07810985
Dis...